JP5256456B2 - 脂質代謝改善剤 - Google Patents
脂質代謝改善剤 Download PDFInfo
- Publication number
- JP5256456B2 JP5256456B2 JP2008507493A JP2008507493A JP5256456B2 JP 5256456 B2 JP5256456 B2 JP 5256456B2 JP 2008507493 A JP2008507493 A JP 2008507493A JP 2008507493 A JP2008507493 A JP 2008507493A JP 5256456 B2 JP5256456 B2 JP 5256456B2
- Authority
- JP
- Japan
- Prior art keywords
- kakrol
- vegetables
- lipid metabolism
- fruit
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000037356 lipid metabolism Effects 0.000 title claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 26
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 244000299906 Cucumis sativus var. sativus Species 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 235000013305 food Nutrition 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 150000004665 fatty acids Chemical class 0.000 description 13
- 230000037213 diet Effects 0.000 description 11
- 244000302512 Momordica charantia Species 0.000 description 10
- 235000009811 Momordica charantia Nutrition 0.000 description 10
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 10
- 240000008067 Cucumis sativus Species 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 235000021110 pickles Nutrition 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 239000002285 corn oil Substances 0.000 description 5
- 235000005687 corn oil Nutrition 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101150037123 APOE gene Proteins 0.000 description 4
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000219104 Cucurbitaceae Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 108010069201 VLDL Cholesterol Proteins 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 238000012364 cultivation method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 241001131796 Botaurus stellaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 240000001740 Momordica dioica Species 0.000 description 2
- 235000018365 Momordica dioica Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- -1 acidulants Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021127 solid diet Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- YGPZWPHDULZYFR-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-amine Chemical compound C1C=C2C[C@@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YGPZWPHDULZYFR-DPAQBDIFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical class C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
九州大学内で栽培したカックロールの青果について、成分及び脂肪酸組成を比較した。対照として、ニガウリ(佐土原3号)を用いた。
カックロール青果を3cm角に切り凍結乾燥し、ミキサーで粉砕した。青果1004gから、淡緑色の粉末131.3gを得た。得られた乾燥物は、苦みはなく、キュウリの味に似ており、青臭い匂いを有した。これを以下の実施例で用いた。
方法:
5週齢の雄SDラットを市販の固形食で1週間予備飼育後、体重により2群に分け、1群6匹とした。AIN-76(米国国立栄養研究所(American Institute of Nutrition, AIN))組成に準じ、5%コーン油を含むコントロール食(コントロール群)、及び5%のコーン油と3%のkakrol凍結乾燥粉末(実施例2)を含むカックロール食(カックロール群)を、摂食量を調節しながら与え、2週間飼育した。
結果を下表に示した。
Kakrolには血清コレステロール濃度の低下作用があり、肝臓脂質の低下作用を示す物質が含まれていることが示唆された。食品成分で同様の作用が見られるものとしては、大豆タンパク質が挙げられるが、その際の食餌中の大豆タンパク質の割合は20%である。3%カックロール食における本実施例での結果は従来の食品成分からは予想できない顕著なものであるといえる。
SDラット又はアポE欠損マウスにカックロール凍結乾燥粉末を摂取させ、カックロールが脂質代謝に及ぼす影響と、その作用機構について検討した。
[実験1 糞中への脂肪酸排泄量の測定]
AIN-76組成に準じて5%コーン油を含む食餌(Control群)と5%コーン油及び3%カックロール凍結乾燥粉末を含む食餌(Kakrol群)、5%コーン油及び3%ニガウリ凍結乾燥粉末を含む食餌(Bitter gourd群)を与えた7週齢の雄SDラットの糞を3日間回収し、滴定により脂肪酸量を測定した。
9〜18週齢の雌雄アポE欠損マウス29匹を市販固形食で1週間予備飼育した後、AIN-76組成に準じ、10%ラードを含むControl食(Control群、雄雌8匹)及び10%ラードと3%のカックロール凍結乾燥粉末を含むカックロール食(Kakrol群、雄6匹、雌7匹)をPair feedingで9週間飼育した。
[実験1 糞中への脂肪酸排泄量の測定]
カックロールの肝臓脂質及び血清コレステロール濃度低下作用は、TGの吸収を抑制することに起因していると示唆された。よって今後はカックロールの脂質吸収阻害の機構を明らかにするため、小腸吸収細胞での脂質の輸送に及ぼす影響を検討する。また今回飼育したアポE欠損マウスの大動脈切片を作成し、カックロールが動脈硬化症の進展に及ぼす影響も評価する予定である。
Claims (7)
- カックロール、及び医薬として許容可能な添加物を含む、高脂血症(原発性(家族性、散発性)、二次性を含む。また、高コレステロール血症を含む。)、脂肪肝、虚血性心疾患(狭心症、心筋梗塞を含む。)、又は脳血管障害(脳梗塞、脳出血を含む。)である脂質代謝に関連した疾患又は状態を処置するための、医薬組成物。
- カックロールが、カックロール青果、その乾燥物、抽出物、分画物、単離物、もしくは濃縮物又はそれらのいずれかの加工物である、請求項1に記載の医薬組成物。
- カックロールを、青果の乾燥物として 10g〜1000gに相当する量で含む、請求項2に記載の医薬組成物。
- カックロールを含む、脂質代謝改善剤。
- カックロールが、カックロール青果、その乾燥物、抽出物、分画物、単離物、もしくは濃縮物又はそれらのいずれかの加工物である、請求項4に記載の脂質代謝改善剤。
- カックロールを含む、脂質吸収阻害剤。
- カックロールが、カックロール青果、その乾燥物、抽出物、分画物、単離物、もしくは濃縮物又はそれらのいずれかの加工物である、請求項6に記載の脂質吸収阻害剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008507493A JP5256456B2 (ja) | 2006-03-24 | 2007-03-26 | 脂質代謝改善剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006083581 | 2006-03-24 | ||
JP2006083581 | 2006-03-24 | ||
JP2008507493A JP5256456B2 (ja) | 2006-03-24 | 2007-03-26 | 脂質代謝改善剤 |
PCT/JP2007/056226 WO2007111306A1 (ja) | 2006-03-24 | 2007-03-26 | 脂質代謝改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007111306A1 JPWO2007111306A1 (ja) | 2009-08-13 |
JP5256456B2 true JP5256456B2 (ja) | 2013-08-07 |
Family
ID=38541223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008507493A Active JP5256456B2 (ja) | 2006-03-24 | 2007-03-26 | 脂質代謝改善剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5256456B2 (ja) |
WO (1) | WO2007111306A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001278804A (ja) * | 2000-03-30 | 2001-10-10 | Miyazaki Prefecture | 脂質代謝改善剤及びそれを含有する食品 |
-
2007
- 2007-03-26 JP JP2008507493A patent/JP5256456B2/ja active Active
- 2007-03-26 WO PCT/JP2007/056226 patent/WO2007111306A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001278804A (ja) * | 2000-03-30 | 2001-10-10 | Miyazaki Prefecture | 脂質代謝改善剤及びそれを含有する食品 |
Non-Patent Citations (4)
Title |
---|
JPN6012038310; Reddy, G.et al: 'Anithyperglycemic activity of Momordica dioica fruits in alloxan-induced diabetic rats' Nigerian Journal of Natural Products and Medicine Vol.9, 2005, pp.33-34 * |
JPN6012038311; Fernandopulle B.M.R.: 'Oral hypoglycaemic effects of Momordica dioica in the rat' Medical Science Research Vol.22,No.2, 1994, pp.137-139 * |
JPN6012038313; Rao, B. Kameswara et al: 'Antidiabetic and hypolipidemic effects of Momordica cymbalaria Hook.fruit powder in alloxan-diabetic' Journal of Ethnopharmacology Vol.67,No.1, 1999, pp.103-109 * |
JPN6012038314; Kameswararao B et al: 'Evaluation of antidiabetic effect of Momordica cymbalaria fruit in alloxan-diabetic rats' Fitoterapia Vol.74, No.1-2, 2003, pp.7-13 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007111306A1 (ja) | 2009-08-13 |
WO2007111306A1 (ja) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dhandapani et al. | Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats | |
TWI329516B (en) | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity | |
US20080124416A1 (en) | Therapeutic composition from goji (lycium barbarum l.), methods of making and using | |
Srinivasa et al. | Fenugreek (Trigonella foenum-graecum L.) seed: promising source of nutraceutical | |
JP2016532724A (ja) | エンブリカのオフィシナリスの種子の抽出物の医療用組成物およびその調製方法 | |
KR101177380B1 (ko) | 옥수수염 추출물, 표고버섯 추출물, 청고추 추출물 및 팥싹 추출물을 함유하는 항비만용 조성물 | |
KR20190002105A (ko) | 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
US20190192601A1 (en) | Extracts of cyclanthera pedata and formulations and uses thereof | |
JP2011504921A (ja) | メタボリック症候群に作用する組成物の調製における植物エクジソンの使用 | |
KR101820096B1 (ko) | 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 | |
Shittu et al. | Hypoglycaemia and improved testicular parameters in Sesamum radiatum treated normo-glycaemic adult male Sprague Dawley rats | |
KR101731859B1 (ko) | 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물 | |
Chaicharoenpong et al. | Use of tea (Camellia oleifera Abel.) seeds in human health | |
Lim et al. | Coix lachryma-jobi | |
JP4325908B2 (ja) | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 | |
KR20160108771A (ko) | 능이버섯 추출물을 포함하는 간 질환의 예방 또는 치료용 조성물 | |
KR20070044198A (ko) | 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제 | |
JP5256456B2 (ja) | 脂質代謝改善剤 | |
KR20150051160A (ko) | 노회 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물 | |
Hassan | Effect of dietary supplementation with tigernut tubers on streptozotocin-induced diabetic rats | |
KR101687270B1 (ko) | 상륙 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물 | |
US20120308586A1 (en) | Composition based on extra virgin olive oils | |
Kumar et al. | The Pharmacological activities of mother of thousand (Kalanchoe pinnata) | |
JP2004137287A (ja) | 高血圧症予防・治療剤 | |
FadlAlla et al. | Hypolipidemic, antioxidant and renal protective effect of seeds mixture rich in omega-3 and omega-6 fatty acids in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120723 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121018 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130322 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |